By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Sapphire Therapeutics, Inc. 

1031 US Highway 22
Suite 303
Bridgewater  New Jersey  08807  U.S.A.
Phone: 908-231-1435 Fax: 908-231-1459


SEARCH JOBS








Company News
Helsinn Healthcare SA Announces the Acquisition of Sapphire Therapeutics, Inc. to Establish Helsinn Therapeutics (US) Inc. 1/28/2009 11:27:12 AM
Sapphire Therapeutics, Inc. Promotes Suzan Allen to Vice President Clinical Operations 2/12/2008 10:12:46 AM
Sapphire Therapeutics, Inc. Licenses Ghrelin Antagonist Program From Novo Nordisk A/S (NVO) for Development of Obesity Treatments 10/30/2007 9:10:24 AM
Sapphire Therapeutics, Inc. Announces Promotions and New Appointment to Management Team 8/9/2007 8:45:15 AM
Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase 2 Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June 4/26/2007 10:27:29 AM
Sapphire Therapeutics, Inc. Promotes William Polvino to CEO 3/27/2007 8:56:37 AM
Sapphire Therapeutics, Inc. Licenses Novel Drug To Ono Pharmaceutical Company, Ltd. In Japan, Korea And Taiwan For The Treatment Of Cancer Anorexia/Cachexia 10/26/2006 10:27:59 AM
Sapphire Therapeutics, Inc. Licenses Ghrelin Mimetic From Novo Nordisk A/S (NVO) 9/19/2006 10:46:55 AM
Sapphire Therapeutics, Inc. Expands Drug Development Team; New CEO, Board Appointment 8/25/2006 10:44:14 AM
Sapphire Therapeutics, Inc. Appoints New Director And Scientific Advisory Board 1/17/2006 11:08:55 AM
12
//-->